These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 27773781)

  • 1. The Na
    Koepsell H
    Pharmacol Ther; 2017 Feb; 170():148-165. PubMed ID: 27773781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of SGLT1 and SGLT2 inhibitors.
    Rieg T; Vallon V
    Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
    Gallo LA; Wright EM; Vallon V
    Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
    Lapuerta P; Zambrowicz B; Strumph P; Sands A
    Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.
    Song P; Onishi A; Koepsell H; Vallon V
    Expert Opin Ther Targets; 2016 Sep; 20(9):1109-25. PubMed ID: 26998950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
    Zambrowicz B; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Boehm KA; Ruff D; Powell D; Sands A
    Clin Ther; 2013 Aug; 35(8):1162-1173.e8. PubMed ID: 23911260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
    Girard J
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
    Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
    J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG.
    Chang HC; Yang SF; Huang CC; Lin TS; Liang PH; Lin CJ; Hsu LC
    Mol Biosyst; 2013 Aug; 9(8):2010-20. PubMed ID: 23657801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors.
    Blaschek W
    Planta Med; 2017 Aug; 83(12-13):985-993. PubMed ID: 28395363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
    Powell DR; Smith M; Greer J; Harris A; Zhao S; DaCosta C; Mseeh F; Shadoan MK; Sands A; Zambrowicz B; Ding ZM
    J Pharmacol Exp Ther; 2013 May; 345(2):250-9. PubMed ID: 23487174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
    Chichger H; Cleasby ME; Srai SK; Unwin RJ; Debnam ES; Marks J
    Exp Physiol; 2016 Jun; 101(6):731-42. PubMed ID: 27164183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2.
    Kanwal A; Singh SP; Grover P; Banerjee SK
    Anal Biochem; 2012 Oct; 429(1):70-5. PubMed ID: 22796500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A selectivity study of sodium-dependent glucose cotransporter 2/sodium-dependent glucose cotransporter 1 inhibitors by molecular modeling.
    Xu J; Yuan H; Ran T; Zhang Y; Liu H; Lu S; Xiong X; Xu A; Jiang Y; Lu T; Chen Y
    J Mol Recognit; 2015 Aug; 28(8):467-79. PubMed ID: 25753971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes.
    Solini A; Rossi C; Mazzanti CM; Proietti A; Koepsell H; Ferrannini E
    Diabetes Obes Metab; 2017 Sep; 19(9):1289-1294. PubMed ID: 28419670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT1 inhibition: Pros and cons.
    Tsimihodimos V; Filippas-Ntekouan S; Elisaf M
    Eur J Pharmacol; 2018 Nov; 838():153-156. PubMed ID: 30240793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
    Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
    Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
    Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
    J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents.
    Du F; Hinke SA; Cavanaugh C; Polidori D; Wallace N; Kirchner T; Jennis M; Lang W; Kuo GH; Gaul MD; Lenhard J; Demarest K; Ajami NJ; Liang Y; Hornby PJ
    J Pharmacol Exp Ther; 2018 Jun; 365(3):676-687. PubMed ID: 29674332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.